DoH Policies screened during the period: 1 January 2021 - 31 March 2021
Date published:
Last updated:
In fulfilling its obligations under Section 75 the Department is required to equality screen all of its policies and services under consideration to determine whether they should be subject to a full equality impact.
Documents
- Screening Template - The COVID-19 vaccination programme
- NICE Technology Appraisal TA663 - Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia
- NICE Technology Appraisal TA664 - Liraglutide for managing overweight and obesity
- NICE Technology Appraisal TA665 - Upadacitinib for treating severe rheumatoid arthritis
- NICE Technology Appraisal TA666 - Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma
- NICE Technology Appraisal TA667 - Caplacizumab with plasma exchange and immunosuppression for treating acute acquired thrombotic thrombocytopenic purpura
- NICE Technology Appraisal TA668 - Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer
- NICE Public Health Guideline NG135 - Alcohol interventions in secondary and further education
- NICE Technology Appraisal TA669 - Trifluridine–tipiracil for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more therapies
- NICE Technology Appraisal TA670 - Brigatinib for ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor
- NICE Technology Appraisal TA679 - Dapagliflozin for treating chronic heart failure with reduced ejection fraction
- NICE Technology Appraisal TA677 - Autologous anti-CD19-transduced CD3+ cells for treating relapsed or refractory mantle cell lymphoma
- NICE Technology Appraisal TA676 - Filgotinib for treating moderate to severe rheumatoid arthritis
- NICE Technology Appraisal TA672 - Brolucizumab for treating wet age-related macular degeneration
- NICE Technology Appraisal TA671 - Mepolizumab for treating severe eosinophilic asthma (review of TA431)
- NICE Technology Appraisal TA673 - Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy
- Online COVID – 19 Vaccination Booking Platform
- Provision of Health Services to Persons Not Ordinarily Resident (Amendment) Regulations (Northern Ireland) 2021
- The Health Protection (Coronavirus, Restrictions) Regulations (Northern Ireland) 2021
- The Health Protection (Coronavirus, International Travel) Regulations (Northern Ireland) 2021
- Autism Interim Strategy 2021-2022
- Making of a Statutory Rule of the Public Health Act (Northern Ireland) 1967, whereby Schedule 1 to the Act (Notifiable Diseases) shall be amended by the insertion of Hepatitis C
- Grant Scheme to support carers
- Adoption and Children Bill 2020
- Continuing healthcare in Northern Ireland
- Policy proposals for the statutory Duty of Candour and Being Open Framework